These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21437102)

  • 1. Saxagliptin for type 2 diabetes.
    Chacra AR
    Diabetes Metab Syndr Obes; 2010 Sep; 3():325-35. PubMed ID: 21437102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical overview of saxagliptin for Type 2 diabetes management.
    Rosenstock J
    Expert Rev Endocrinol Metab; 2010 Nov; 5(6):809-823. PubMed ID: 30780831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
    Hollander PA; Kushner P
    Postgrad Med; 2010 May; 122(3):71-80. PubMed ID: 20463416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
    Karyekar CS; Ravichandran S; Allen E; Fleming D; Frederich R
    Clin Interv Aging; 2013; 8():419-30. PubMed ID: 23626461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.
    Kulasa K; Edelman S
    Core Evid; 2010 Oct; 5():23-37. PubMed ID: 21042540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.
    Sharma MD
    Ther Clin Risk Manag; 2010 May; 6():233-7. PubMed ID: 20526441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
    Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
    Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
    Yang LP
    Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
    Konya H; Yano Y; Matsutani S; Tsunoda T; Ikawa T; Kusunoki Y; Matsuo T; Miuchi M; Katsuno T; Hamaguchi T; Miyagawa J; Namba M
    Ther Clin Risk Manag; 2014; 10():547-58. PubMed ID: 25050065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Tahrani AA; Piya MK; Barnett AH
    Adv Ther; 2009 Mar; 26(3):249-62. PubMed ID: 19330494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M; Iqbal N; Lu J; Hirshberg B
    Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
    Gallwitz B
    Diabetes Metab Syndr Obes; 2010 May; 3():117-24. PubMed ID: 21437082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin.
    Dhillon S; Weber J
    Drugs; 2009 Oct; 69(15):2103-14. PubMed ID: 19791828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
    Schwartz SL
    Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.
    Gautier JF; Sauvanet JP
    Ann Endocrinol (Paris); 2011 Sep; 72(4):287-295. PubMed ID: 21777901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.
    LaSalle JR
    Postgrad Med; 2010 Jan; 122(1):144-52. PubMed ID: 20107298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.